Correlation Between Mineralys Therapeutics, and Halozyme Therapeutics

Can any of the company-specific risk be diversified away by investing in both Mineralys Therapeutics, and Halozyme Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Mineralys Therapeutics, and Halozyme Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Mineralys Therapeutics, Common and Halozyme Therapeutics, you can compare the effects of market volatilities on Mineralys Therapeutics, and Halozyme Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Mineralys Therapeutics, with a short position of Halozyme Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Mineralys Therapeutics, and Halozyme Therapeutics.

Diversification Opportunities for Mineralys Therapeutics, and Halozyme Therapeutics

0.61

Correlation Coefficient

Mineralys Therapeutics,  Halozyme Therapeutics

Poor diversification

The 3 months correlation between Mineralys and Halozyme is 0.61. Overlapping area represents the amount of risk that can be diversified away by holding Mineralys Therapeutics, Common and Halozyme Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Halozyme Therapeutics and Mineralys Therapeutics, is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Mineralys Therapeutics, Common are associated (or correlated) with Halozyme Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Halozyme Therapeutics has no effect on the direction of Mineralys Therapeutics, i.e., Mineralys Therapeutics, and Halozyme Therapeutics go up and down completely randomly.

Pair Corralation between Mineralys Therapeutics, and Halozyme Therapeutics

Given the investment horizon of 90 days Mineralys Therapeutics, Common is expected to generate 1.38 times more return on investment than Halozyme Therapeutics. However, Mineralys Therapeutics, is 1.38 times more volatile than Halozyme Therapeutics. It trades about -0.01 of its potential returns per unit of risk. Halozyme Therapeutics is currently generating about -0.13 per unit of risk. If you would invest  1,351  in Mineralys Therapeutics, Common on October 6, 2024 and sell it today you would lose (76.00) from holding Mineralys Therapeutics, Common or give up 5.63% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Significant
Accuracy	100.0%
Values	Daily Returns

Mineralys Therapeutics, Common  vs.  Halozyme Therapeutics

Mineralys Therapeutics,

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Mineralys Therapeutics, Common has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable basic indicators, Mineralys Therapeutics, is not utilizing all of its potentials. The current stock price uproar, may contribute to short-horizon losses for the private investors.

Halozyme Therapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Halozyme Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest unfluctuating performance, the Stock's essential indicators remain healthy and the recent disarray on Wall Street may also be a sign of long period gains for the firm investors.

Pair Trading with Mineralys Therapeutics, and Halozyme Therapeutics

The main advantage of trading using opposite Mineralys Therapeutics, and Halozyme Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Mineralys Therapeutics, position performs unexpectedly, Halozyme Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Halozyme Therapeutics will offset losses from the drop in Halozyme Therapeutics' long position.

The idea behind Mineralys Therapeutics, Common and Halozyme Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.